Introduction
Although modern anti-retroviral therapy (ART) permits near-normal life expectancies by suppressing viral replication to clinically undetectable levels in people living with HIV (PLWH) (1), sustained treatment is complicated by complex pharmacological (i.e., adverse events, adherence, resistance) and societal issues (i.e., stigma, cost burden, medical access). Furthermore, ART is incapable of eliminating the latent viral reservoir, which is responsible for recrudescence when therapy is interrupted (2–5). Viral persistence is facilitated by a variety of mechanisms such as the exhaustion of HIV-specific cytolytic T-cells (CTLs) driven by chronic inflammation (6–8); epigenetic modifications to dampen the expression of viral proteins allowing evasion of immunosurveillance (9, 10); the localization of infected cells within immune privileged anatomical sites (11–13); and the survival of long-lived, virus-harboring cells allowing reservoir expansion via homeostatic proliferation (14, 15). Although formidable challenges exist for completing eradicating HIV from infected individuals (a “cure”), there is growing enthusiasm that novel immunotherapy approaches might eventually result in durable control of replication-competent HIV in absence of any therapy (a “remission”). Much of this enthusiasm comes from dramatic progress made in using immunotherapy to treating cancer. This editorial summarizes how the 13 review articles included in this special issue highlight key parallels between HIV and tumor persistence as well as how these similarities inform the development of novel immunotherapy-based strategies toward an HIV cure.
The Persistence of Memory
In both HIV and cancer, subsequent pathology arises from a relatively rare, yet difficult to distinguish and persistent subset of cells. In the non-human primate model of HIV infection, the persistent viral reservoir is established within 4–9 days post-infection (16); similarly, very early ART initiation does not induce viral remission in PLWH (17). In a meta-analysis of human cohorts, Etemad et al. propose that preferential infection of transitional memory (TTM) CD4+ T-cells, as opposed to longer-lived central memory or naïve cells, is a key predictor for post-treatment control (18) despite weak HIV-specific CD8+ T-cell responses. Intriguingly, Goonetilleke et al. hypothesize that the generation of the long-lived reservoir, particularly in central memory (TCM) and stem-cell memory (TSCM) CD4+ T-cells, can be blunted by inhibiting the IL-7 signaling axis, thereby disrupting the transition and maintenance of CD127+ memory subsets from highly-infected effector CD4+ T-cells (18). Gavegnano et al. explore the use of Jak inhibitors in inhibiting the activity of the anti-apoptotic Bcl-2 protein to reduce cellular lifespans (19, 20). By blocking the formation and maintenance of the viral reservoir in long-lived memory subsets, the authors proposed that a reduction in viral burden will facilitate HIV remission as mimicked in post-treatment controllers.
Escape Through Editing
Once the viral reservoir is established, HIV-specific CD8+ T-cells are required for viral suppression (21, 22); however, in most infected people, HIV-specific CTLs are incapable of eliminating infected cells (23) indicative of failure in immune surveillance independent of mutational escape or dysfunction (24). This incomplete elimination permits subsequent equilibrium phase sculpting of reservoir-harboring cells by immune pressures, which in cancer models has been termed “immunoediting” (25). Analogous to “antigen loss” in tumors models, Huang et al. explore the novel concept that during ART cells harboring replication-competent virus undergo clonal expansion with subsequent immunoediting; thereby decreasing CTL susceptibility by selecting for BCL-2 expression (26) and integration sites favoring cell division (27, 28). As HIV infection impacts on cellular metabolism and oxidative stress (29, 30), immunoediting may also select for an altered cellular lipid antigen composition that, as summarized by Tiwary et al., in oncology models impinges on chronic inflammation by modulating the macrophage M1 to M2 balance (31) and impairs antigen processing in dendritic cells (32); specifically, CD1d antigen loading for natural killer T-cells (NKT) (33). As a model comparison (Mota and Jones) examine how HTLV-1 generates malignant “repliclones” by an interplay of host- and viral-mediated immunoediting. Therefore, these articles support the notion that HIV CTL escape might be more complex than viral epitope mutations, but rather involve the progressive selection of immunoedited, infected cells resistant to immune surveillance.
Who Watches the Watchmen?
Effective immunosurveillance of HIV-infected cells remains problematic as CTLs exhibit exhausted effector functions arising from chronic inflammation and antigen persistence during the natural course of infection and residual inflammation, driven by microbial translocation in the gut, despite suppressive ART (34, 35). Structural defects in gut integrity cause by HIV further impacts the microbiota distribution (36), which given its ability in cancer models to modulate toxicity (37) and therapy efficacy (38, 39), may represent an attractive therapeutic avenue as proposed by Herrera et al.. In some respects, as describe by Dhodapkar and Dhodapkar, ART-suppressed HIV mirrors pre-clinical malignancy, a prolonged state characterized by early-onset of T-cell exhaustion coupled with the depletion of stem cell memory (40). However, unlike antigen-rich tumor models, curative HIV therapies require that latent virus be reactivated to render infected cells immunogenic and cleared by potent anti-HIV CTLs (“kick and kill”) (10, 41). Given their capacity to promote tumor clearance, as detailed by Puronen et al., many immunotherapies are being investigated in HIV cure studies to induce T-cell activation and restore CTL functionality, such anti-PD-1 and anti-CTLA-4 check point inhibitors (CPI) (42–44), and IL-7 and IL-15 cytokine therapy (45, 46). Given emerging data concerning the importance of innate natural killer (NK) cells in the control of HIV and cancers (47, 48), Lucar et al., discuss immunotherapies targeting NKG2a and killer-cell immunoglobulin-like receptors (KIRs) as novel strategies to determine whether dysfunction NK cell states can be rescued. Curative strategies centered around CPIs have revolutionized the treatment of certain refractory cancers by reinvigorating the host immune response; yet, in PWLH it remains to be seen whether antigen burden is a critical determinant of response.
In Case of Emergency—Break Glass
Beyond these strategies, which may above prove too toxic, fail to penetrate tissue, or lack desire specificity, alternative curative approaches utilize adoptive T-cell therapy to redirect CTL responses. Kim et al. describe the re-emergence of chimeric antigen receptor (CAR) T-cells as an attractive immunotherapy strategy given its progressive re-engineering in oncology settings to improve safety, expression, and persistence (49). Although CAR T-cells have attained remarkable remission rates for CD19+ B-cell acute lymphoblastic leukemia (50), significant relapse rates are associated with diminished persistence upon antigen loss/escape, the suppressive tumor microenvironment, and impaired tumor penetration (51). These issue impacting tumor relapse are directly analogous to HIV models vis-á-vis ART-mediated aviremia, the expansion of regulatory T-cells (TREGs) (52, 53), and the exclusion of CTLs from secondary lymphoid tissue (13, 54). Possible strategies to surmount these issues include engineering CAR T-cells to express 4-1BB co-stimulatory domains allowing oxidative metabolism (55); secrete cytokines, such as IL-12 or IL-18 (56, 57); and up-regulate the chemokine receptor CXCR5 to promote homing to the lymphoid B-cell follicle (58) as explored by Mylvaganam et al.. Seemingly, CAR T-cells for HIV applications should be directed against viral proteins to minimize safety concerns and given the lack of reliable biomarkers to identify latently-infected cells. Ergo, CAR T-cells will likely require co-administration with potent latency reactivating agents to promote therapy persistence and reveal cellular targets for clearance. Such combination therapies would benefit from positron emission tomography (PET)-based imaging, as reviewed by Henrich et al., to observe the total-body viral antigen distribution (59, 60) and to gain insights concerning the potential for efficacy in difficult to sample tissues (61, 62).
Summary
Models of cancer and HIV persistence share an interesting paradox: responses promoting self-tolerance when exposed to sustained inflammatory stimuli permit pathological dissemination and escape from immune surveillance. This similarity would suggest common curative approaches via the targeting of immunosuppressive pathways. However, a key distinction is that in cancer the self-immunogen is pervasive; whereas, in ART-treated HIV infection chronic antigenic stimulation arises largely from gut microbial translocation, not from viral proteins. This different in antigen source may represent a key obstacle when translating therapies between cancer and HIV models (63). In designing immunotherapy strategies, it is also important to consider that adverse event outcomes between these models have substantially different tolerances, as HIV is a manageable chronic disease and cancers are invariably fatal. Future trials will be necessary to determine whether these mechanistic insights regarding escape and exhaustion can be successfully adapted to facilitate long-term, ART-free HIV remission.
Statements
Author contributions
MP, KD, SD, and RA contributed to formulating the theme for this article collection, recruiting authors, and acting as editors for the submissions. MP and JH wrote the editorial, with contributions, and final edits from all authors.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. (2017) 4:e349–56. 10.1016/S2352-3018(17)30066-8
2.
SilicianoJDKajdasJFinziDQuinnTCChadwickKMargolickJBet al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med. (2003) 9:727–8. 10.1038/nm880
3.
FinziDBlanksonJSilicianoJDMargolickJBChadwickKPiersonTet al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. (1999) 5:512–7. 10.1038/8394
4.
ChunTWDaveyRTJrEngelDLaneHCFauciAS. Re-emergence of HIV after stopping therapy. Nature. (1999) 401:874–5. 10.1038/44755
5.
DaveyRTJrBhatNYoderCChunTWMetcalfJADewarRet al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci USA. (1999) 96:15109–14. 10.1073/pnas.96.26.15109
6.
DayCLKaufmannDEKiepielaPBrownJAMoodleyESReddySet al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature. (2006) 443:350–4. 10.1038/nature05115
7.
TrautmannLJanbazianLChomontNSaidEAGimmigSBessetteBet al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. (2006) 12:1198–202. 10.1038/nm1482
8.
D'SouzaMFontenotAPMackDGLozuponeCDillonSMeditzAet al. Programmed death 1 expression on HIV-specific CD4+ T cells is driven by viral replication and associated with T cell dysfunction. J Immunol. (2007) 179:1979–87. 10.4049/jimmunol.179.3.1979
9.
ArchinNMKeedyKSEspesethADangHHazudaDJMargolisDM. Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors. AIDS. (2009) 23:1799–806. 10.1097/QAD.0b013e32832ec1dc
10.
ArchinNMLibertyALKashubaADChoudharySKKurucJDCrooksAMet al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. (2012) 487:482–5. 10.1038/nature11286
11.
BangaRProcopioFANotoAPollakisGCavassiniMOhmitiKet al. PD-1(+) and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat Med. (2016) 22:754–61. 10.1038/nm.4113
12.
FukazawaYLumROkoyeAAParkHMatsudaKBaeJYet al. B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers. Nat Med. (2015) 21:132–9. 10.1038/nm.3781
13.
ConnickEMattilaTFolkvordJMSchlichtemeierRMeditzALRayMGet al. CTL fail to accumulate at sites of HIV-1 replication in lymphoid tissue. J Immunol. (2007) 178:6975–83. 10.4049/jimmunol.178.11.6975
14.
ChomontNEl-FarMAncutaPTrautmannLProcopioFAYassine-DiabBet al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. (2009) 15:893–900. 10.1038/nm.1972
15.
BuzonMJSunHLiCShawASeissKOuyangZet al. HIV-1 persistence in CD4+ T cells with stem cell-like properties. Nat Med. (2014) 20:139–42. 10.1038/nm.3445
16.
OkoyeAAHansenSGVaidyaMFukazawaYParkHDuellDMet al. Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound. Nat Med. (2018) 24:1430–40. 10.1038/s41591-018-0130-7
17.
ColbyDJTrautmannLPinyakornSLeyreLPagliuzzaAKroonEet al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat Med. (2018) 24:923–6. 10.1038/s41591-018-0026-6
18.
ShanLDengKGaoHXingSCapoferriAADurandCMet al. Transcriptional reprogramming during effector-to-memory transition renders CD4(+) T cells permissive for latent hiv-1 infection. Immunity. (2017) 47:766–75.e3. 10.1016/j.immuni.2017.09.014
19.
ChetouiNBoisvertMGendronSAoudjitF. Interleukin-7 promotes the survival of human CD4+ effector/memory T cells by up-regulating Bcl-2 proteins and activating the JAK/STAT signalling pathway. Immunology. (2010) 130:418–26. 10.1111/j.1365-2567.2009.03244.x
20.
GavegnanoCBrehmJHDupuyFPTallaARibeiroSPKulpaDAet al. Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors. PLoS Pathog. (2017) 13:e1006740. 10.1371/journal.ppat.1006740
21.
McBrienJBMavignerMFranchittiLSmithSAWhiteETharpGKet al. Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8(+) cells. Nature. (2020) 578:154–9. 10.1038/s41586-020-1946-0
22.
CartwrightEKSpicerLSmithSALeeDFastRPaganiniSet al. CD8(+) lymphocytes are required for maintaining viral suppression in SIV-infected macaques treated with short-term antiretroviral therapy. Immunity. (2016) 45:656–68. 10.1016/j.immuni.2016.08.018
23.
CollinsKLChenBKKalamsSAWalkerBDBaltimoreD. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature. (1998) 391:397–401. 10.1038/34929
24.
HuangSHRenYThomasASChanDMuellerSWardARet al. Latent HIV reservoirs exhibit inherent resistance to elimination by CD8+ T cells. J Clin Invest. (2018) 128:876–89. 10.1172/JCI97555
25.
DunnGPBruceATIkedaHOldLJSchreiberRD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. (2002) 3:991–8. 10.1038/ni1102-991
26.
RenYHuangSHPatelSConce AlbertoWDMagatDAhimovicDJet al. BCL-2 antagonism sensitizes cytotoxic t cell-resistant hiv reservoirs to elimination ex vivo. J Clin Invest. (2020). 10.1172/JCI132374
27.
WagnerTAMcLaughlinSGargKCheungCYLarsenBBStyrchakSet al. HIV latency. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science. (2014) 345:570–3. 10.1126/science.1256304
28.
MaldarelliFWuXSuLSimonettiFRShaoWHillSet al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science. (2014) 345:179–83. 10.1126/science.1254194
29.
FunderburgNTMehtaNN. Lipid abnormalities and inflammation in HIV inflection. Curr HIV/AIDS Rep. (2016) 13:218–25. 10.1007/s11904-016-0321-0
30.
LakeJECurrierJS. Metabolic disease in HIV infection. Lancet Infect Dis. (2013) 13:964–75. 10.1016/S1473-3099(13)70271-8
31.
BuckleyCDGilroyDWSerhanCN. Proresolving lipid mediators and mechanisms in the resolution of acute inflammation. Immunity. (2014) 40:315–27. 10.1016/j.immuni.2014.02.009
32.
HerberDLCaoWNefedovaYNovitskiySVNagarajSTyurinVAet al. Lipid accumulation and dendritic cell dysfunction in cancer. Nat Med. (2010) 16:880–6. 10.1038/nm.2172
33.
GadolaSDSilkJDJeansAIllarionovPASalioMBesraGSet al. Impaired selection of invariant natural killer T cells in diverse mouse models of glycosphingolipid lysosomal storage diseases. J Exp Med. (2006) 203:2293–303. 10.1084/jem.20060921
34.
BrenchleyJMPriceDASchackerTWAsherTESilvestriGRaoSet al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. (2006) 12:1365–71. 10.1038/nm1511
35.
SchuetzADeleageCSeretiIRerknimitrRPhanuphakNPhuang-NgernYet al. Initiation of ART during early acute HIV infection preserves mucosal Th17 function and reverses HIV-related immune activation. PLoS Pathog. (2014) 10:e1004543. 10.1371/journal.ppat.1004543
36.
Vujkovic-CvijinIDunhamRMIwaiSMaherMCAlbrightRGBroadhurstMJet al. Dysbiosis of the gut microbiota is associated with HIV disease progression and tryptophan catabolism. Sci Transl Med. (2013) 5:193ra191. 10.1126/scitranslmed.3006438
37.
WangYWiesnoskiDHHelminkBAGopalakrishnanVChoiKDuPontHLet al. Fecal microbiota transplantation for refractory immune checkpoint inhibitor-associated colitis. Nat Med. (2018) 24:1804–8. 10.1038/s41591-018-0238-9
38.
VetizouMPittJMDaillereRLepagePWaldschmittNFlamentCet al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. (2015) 350:1079–84. 10.1126/science.aad1329
39.
GopalakrishnanVSpencerCNNeziLReubenAAndrewsMCKarpinetsTVet al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. (2018) 359:97–103. 10.1126/science.aan4236
40.
BailurJKMcCachrenSSDoxieDBShresthaMPendletonKNookaAKet al. Early alterations in stem-like/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy. JCI Insight. (2019) 5:e127807. 10.1172/jci.insight.127807
41.
DeeksSG. HIV: shock and kill. Nature. (2012) 487:439–40. 10.1038/487439a
42.
WightmanFSolomonAKumarSSUrriolaNGallagherKHienerBet al. Effect of ipilimumab on the HIV reservoir in an HIV-infected individual with metastatic melanoma. AIDS. (2015) 29:504–6. 10.1097/QAD.0000000000000562
43.
EvansVAvan der SluisRMSolomonADantanarayanaAMcNeilCGarsiaRet al. Programmed cell death-1 contributes to the establishment and maintenance of HIV-1 latency. AIDS. (2018) 32:1491–7. 10.1097/QAD.0000000000001849
44.
GuihotAMarcelinAGMassianiMASamriASoulieCAutranBet al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol. (2018) 29:517–8. 10.1093/annonc/mdx696
45.
GarridoCAbad-FernandezMTuyishimeMPollaraJJFerrariGSoriano-SarabiaNet al. Interleukin-15-stimulated natural killer cells clear HIV-1-infected cells following latency reversal ex vivo. J Virol. (2018) 92:e00235-18. 10.1128/JVI.00235-18
46.
LogerotSRancezMCharmeteau-de MuylderBFigueiredo-MorgadoSRozlanSTambussiGet al. HIV reservoir dynamics in HAART-treated poor immunological responder patients under IL-7 therapy. AIDS. (2018) 32:715–20. 10.1097/QAD.0000000000001752
47.
RamsuranVNaranbhaiVHorowitzAQiYMartinMPYukiYet al. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A-expressing cells. Science. (2018) 359:86–90. 10.1126/science.aam8825
48.
Lo MonacoETremanteECerboniCMelucciESibilioLZingoniAet al. Human leukocyte antigen E contributes to protect tumor cells from lysis by natural killer cells. Neoplasia. (2011) 13:822–30. 10.1593/neo.101684
49.
LeibmanRSRichardsonMWEllebrechtCTMaldiniCRGloverJASecretoAJet al. Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor. PLoS Pathog. (2017) 13:e1006613. 10.1371/journal.ppat.1006613
50.
MaudeSLLaetschTWBuechnerJRivesSBoyerMBittencourtHet al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. (2018) 378:439–48. 10.1056/NEJMoa1709866
51.
O'RourkeDMNasrallahMPDesaiAMelenhorstJJMansfieldKMorrissetteJJDet al. A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci Transl Med. (2017) 9:eaaa0984. 10.1126/scitranslmed.aaa0984
52.
KinterAMcNallyJRigginLJacksonRRobyGFauciAS. Suppression of HIV-specific T cell activity by lymph node CD25+ regulatory T cells from HIV-infected individuals. Proc Natl Acad Sci USA. (2007) 104:3390–5. 10.1073/pnas.0611423104
53.
WeissLDonkova-PetriniVCaccavelliLBalboMCarbonneilCLevyY. Human immunodeficiency virus-driven expansion of CD4+CD25+ regulatory T cells, which suppress HIV-specific CD4 T-cell responses in HIV-infected patients. Blood. (2004) 104:3249–56. 10.1182/blood-2004-01-0365
54.
ConnickEFolkvordJMLindKTRakaszEGMilesBWilsonNAet al. Compartmentalization of simian immunodeficiency virus replication within secondary lymphoid tissues of rhesus macaques is linked to disease stage and inversely related to localization of virus-specific CTL. J Immunol. (2014) 193:5613–25. 10.4049/jimmunol.1401161
55.
KawalekarOUO'ConnorRSFraiettaJAGuoLMcGettiganSEPoseyADJret al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. (2016) 44:380–90. 10.1016/j.immuni.2016.01.021
56.
YekuOOPurdonTJKoneruMSpriggsDBrentjensRJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep. (2017) 7:10541. 10.1038/s41598-017-10940-8
57.
HuBRenJLuoYKeithBYoungRMSchollerJet al. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep. (2017) 20:3025–33. 10.1016/j.celrep.2017.09.002
58.
HaranKPHajduczkiAPampuschMSMwakalundwaGVargas-InchausteguiDARakaszEGet al. Simian Immunodeficiency Virus (SIV)-specific chimeric antigen receptor-T cells engineered to target B cell follicles and suppress SIV replication. Front Immunol. (2018) 9:492. 10.3389/fimmu.2018.00492
59.
SantangeloPJRogersKAZurlaCBlanchardELGumberSStraitKet al. Whole-body immunoPET reveals active SIV dynamics in viremic and antiretroviral therapy-treated macaques. Nat Methods. (2015) 12:427–32. 10.1038/nmeth.3320
60.
SantangeloPJCicalaCByrareddySNOrtizKTLittleDLindsayKEet al. Early treatment of SIV+ macaques with an alpha4beta7 mAb alters virus distribution and preserves CD4(+) T cells in later stages of infection. Mucosal Immunol. (2018) 11:932–46. 10.1038/mi.2017.112
61.
LamersSLRoseRMaidjiEAgsalda-GarciaMNolanDJFogelGBet al. HIV DNA is frequently present within pathologic tissues evaluated at autopsy from combined antiretroviral therapy-treated patients with undetectable viral loads. J Virol. (2016) 90:8968–83. 10.1128/JVI.00674-16
62.
EstesJDKityoCSsaliFSwainsonLMakamdopKNDel PreteGQet al. Defining total-body AIDS-virus burden with implications for curative strategies. Nat Med. (2017) 23:1271–6. 10.1038/nm.4411
63.
BekermanEHesselgesserJCarrBNagelMHungMWangAet al. PD-1 blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy. Antimicrob Agents Chemother. 63:e01163-19. 10.1128/AAC.01163-19
Summary
Keywords
HIV, cancer, ART, immunotherapy, immune surveillance, immune checkpoint blockade, inflammation, CAR T cells
Citation
Paiardini M, Dhodapkar K, Harper J, Deeks SG and Ahmed R (2020) Editorial: HIV and Cancer Immunotherapy: Similar Challenges and Converging Approaches. Front. Immunol. 11:519. doi: 10.3389/fimmu.2020.00519
Received
27 February 2020
Accepted
06 March 2020
Published
31 March 2020
Volume
11 - 2020
Edited and reviewed by
Catherine Sautes-Fridman, INSERM U1138 Centre de Recherche des Cordeliers, France
Updates
Copyright
© 2020 Paiardini, Dhodapkar, Harper, Deeks and Ahmed.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Mirko Paiardini mirko.paiardini@emory.edu
This article was submitted to Cancer Immunity and Immunotherapy, a section of the journal Frontiers in Immunology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.